NASDAQ:NVUS Novus Therapeutics (NVUS) Stock Price, News & Analysis → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free NVUS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.27▼$2.4950-Day Range$9.85▼$16.5052-Week Range$4.50▼$27.32Volume170,571 shsAverage Volume78,851 shsMarket Capitalization$3.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Novus Therapeutics alerts: Email Address Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> About Novus Therapeutics Stock (NASDAQ:NVUS)Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Read More Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> NVUS Stock News HeadlinesMarch 1, 2024 | morningstar.comVivoryon Therapeutics NV VVYFebruary 22, 2024 | money.usnews.comViking Therapeutics IncMay 10, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.December 28, 2023 | seekingalpha.comCYT Cyteir Therapeutics, Inc.May 11, 2023 | finance.yahoo.comNovo Holdings invests in US$105 million Series C Funding of Alentis TherapeuticsMarch 31, 2023 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR), Analyst Ratings, Price Targets, PredictionsMarch 30, 2023 | finance.yahoo.comSales Revenue from CNS Therapeutics Market to Top US$ 142.1 Billion by 2026: Fact.MR AnalysisMarch 29, 2023 | proactiveinvestors.comChimeric Therapeutics welcomes “positive” feedback following pre-IND meeting with US FDA for Phase 1 CAR-T studyMay 10, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 25, 2023 | usnews.comEast Career Technical AcademyMarch 25, 2023 | usnews.comLas Vegas Academy of the ArtsFebruary 22, 2023 | money.usnews.comPerspective Therapeutics IncFebruary 12, 2023 | finance.yahoo.comOnychomycosis Therapeutics Market Size Worth US$ ~8,420.3 million , Globally, by 2030 at 6% CAGRSee More Headlines Receive NVUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2020Today5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVUS CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone949-238-8090FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($21.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-133.49% Return on Assets-30.52% Debt Debt-to-Equity RatioN/A Current Ratio18.78 Quick Ratio18.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.13 per share Price / Book0.18Miscellaneous Outstanding Shares1,436,000Free FloatN/AMarket Cap$3.45 million OptionableNot Optionable Beta2.07 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jon S. Kuwahara CPA (Age 55)CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer Comp: $295.72kMr. Gregory J. Flesher (Age 50)Consultant Comp: $482.13kDr. David-Alexandre C. Gros M.D. (Age 48)CEO & Non Independent Director Dr. Steven N. Perrin Ph.D. (Age 55)Pres, Chief Scientific Officer & Non Independent Director Key CompetitorsAridis PharmaceuticalsNASDAQ:ARDSBiophytisNASDAQ:BPTSYNovaBay PharmaceuticalsNYSE:NBYPhaseBio PharmaceuticalsNASDAQ:PHASClever LeavesNASDAQ:CLVRView All Competitors NVUS Stock Analysis - Frequently Asked Questions How were Novus Therapeutics' earnings last quarter? Novus Therapeutics, Inc. (NASDAQ:NVUS) posted its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) EPS for the quarter, missing the consensus estimate of ($1.64) by $3.87. Read the conference call transcript. When did Novus Therapeutics' stock split? Novus Therapeutics's stock reverse split before market open on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Novus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM) and vTv Therapeutics (VTVT). This page (NASDAQ:NVUS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.